Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of These 10 Stocks Are Making Big Moves.

Viking Therapeutics jumped by 9.74 percent on Tuesday to close at $30.19 apiece as investors repositioned portfolios ahead of the expected release of the results of its own weight loss drug clinical trial.

In a statement, Viking Therapeutics, Inc. (NASDAQ:VKTX) said it expects to report the phase 2 trial data for its weight loss drug candidate VK2735 after 13 weeks of trial. The trial enrolled late in March approximately 280 obese adults with at least one weight-related co-morbid condition.

The primary endpoint of the study is to find the percentage change in body weight from baseline after 13 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures.

Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

A microbiologist in protective gear studying samples in a laboratory.

Viking Therapeutics, Inc. (NASDAQ:VKTX) previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers.

According to the company, receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2 percent.

While we acknowledge the risk and potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VKTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.